Stock Markets March 11, 2026

Gerresheimer Says FY25 Audited Results Will Be Delayed to June 2026, Faces SDAX Removal

Second external audit probe prolongs reporting timetable, forcing talks with creditors and postponement of key corporate dates

By Caleb Monroe
Gerresheimer Says FY25 Audited Results Will Be Delayed to June 2026, Faces SDAX Removal

Gerresheimer AG has announced it will miss the March 31 deadline to publish its audited financial statements for fiscal 2025 after a second external auditor's review of transactions covering 2024 and 2025 took longer than anticipated. The company now expects to release audited annual and consolidated results in June 2026. The delay will lead to the firm being dropped from Deutsche Boerse AG's SDAX index and has prompted negotiations with lenders over covenant deadlines. Several corporate events, including a first-quarter trading update and the Annual General Meeting, will be postponed.

Key Points

  • Gerresheimer will miss the March 31 deadline for audited FY25 financial statements and now expects publication in June 2026.
  • The delay will result in Gerresheimer's exclusion from Deutsche Boerse AG's SDAX index and has prompted negotiations with creditors over financing covenant deadlines.
  • Planned corporate events including the Q1 2026 trading update (previously set for April 16) and the Annual General Meeting scheduled for June 3 are being postponed.

Gerresheimer AG said on Tuesday it will not meet the March 31 deadline to publish its audited financial statements for the 2025 fiscal year, citing a protracted review by a second external auditing firm of business transactions spanning financial years 2024 and 2025. The German manufacturer of pharmaceutical packaging and drug delivery systems now aims to publish audited annual and consolidated accounts in June 2026.

In a regulatory filing, the Duesseldorf-based company said the additional external audit work and the preparation of documentation needed for that review "are taking longer than expected." The filing did not disclose the identity of the second auditor, the specific transactions under scrutiny, or what prompted the supplementary investigation.

Gerresheimer warned that the delayed publication will trigger the exclusion of its shares from Deutsche Boerse AG's SDAX index. The company said it has entered discussions with its creditors to seek extensions for audited-statement submission deadlines that are set out in its financing agreements, a move that signals potential covenant implications arising from the reporting setback.

The disruption to reporting affects multiple points on Gerresheimer's calendar. The company said a first-quarter 2026 trading update, which had been scheduled for April 16, will be postponed to an unspecified later date. In addition, the Annual General Meeting, originally arranged for June 3, cannot go ahead as planned; Gerresheimer said it will announce a rescheduled date in due course.

Gerresheimer supplies primary packaging and drug delivery systems to the pharmaceutical and healthcare sectors and trades on the Frankfurt Stock Exchange. The company emphasized the ongoing nature of the external probe and the need to complete audit documentation before filing audited results.

Separately, promotional material included with the original report noted that ProPicks AI evaluates the ticker GXId among thousands of companies using more than 100 financial metrics to assess fundamentals, momentum, and valuation. That material also cited past ProPicks AI winners, naming Super Micro Computer (+185%) and AppLovin (+157%), and invited readers to check whether GXId appears in current strategies.


Context note: The filing and corporate schedule changes outlined above reflect the company statement; the regulatory disclosure did not provide additional detail on the transactions under review or the second auditor's identity.

Risks

  • Index exclusion - The removal from the SDAX may affect share liquidity and index-linked investor exposure, impacting market participants and equity trading.
  • Financing covenant risks - The company is negotiating deadline extensions with creditors, indicating potential covenant implications tied to audited-statement timing, which could affect corporate financing terms.
  • Audit uncertainty - The second auditor's investigation into transactions for 2024 and 2025 has not been detailed, leaving unresolved questions about the scope and potential consequences for the company's financial reporting.

More from Stock Markets

Barclays Says Hyperscaler AI Hardware Spending Could Be Hundreds of Billions Higher Than Forecast Through 2028 Mar 11, 2026 Barclays Warns European Stocks Vulnerable if Crude Holds Near $100 Mar 11, 2026 3i Infrastructure to take majority stake in Norway’s Lefdal Mine Datacenter Mar 11, 2026 Stellantis Raises 5 Billion Euros Through Multi-Tranche Hybrid Bond Sale After EV Charge Reset Mar 11, 2026 European Stocks Slide as Middle East Conflict and Corporate News Weigh on Markets Mar 11, 2026